Topic
Lipid nanoparticles that encapsulate and deliver RNA or other therapeutic payloads into cells, widely used in mRNA vaccines and gene therapies.
Georgia Tech and Emory researchers found the gut site where a lipid-nanoparticle mRNA dose lands, cheek to rectum, changes which organs it reaches in mice. That turns the delivery site into a tool for aiming oral vaccines at lymph nodes or GLP-1 therapy at the pancreas.
Reality
Ninety percent of drug candidates that reach human trials are never approved. A Norwegian group argues some of that triage belongs in donor blood, where nanoparticles meet the plasma proteins and immune cells that settle their fate.
Reality
A University of Toronto group packed engineered tRNAs into inhalable lipid nanoparticles and recovered full-length CFTR in three model systems, which turns a mutation class gene editing struggles with into a question about delivery and dosing.
Reality
In mice, a peptide-PEG agent given before dosing cut liver expression several dozenfold and raised spleen expression severalfold, according to work in ACS Nano.
Reality
Nagoya University and FUJIFILM report longer-lasting expression from capped circular RNA in a new lipid nanoparticle. The mouse data are directional; the duration numbers are not public yet.
Reality
A lipid nanoparticle that carries antigen mRNA, STING mRNA and a delayed-release activator addresses the reason cGAS-STING adjuvants keep failing: the agonist shuts down antigen translation.
Reality